CN Patent

CN109153669A — N-[5-(3,5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氢吡喃-4-基氨基)-苯甲酰胺的新晶型

Assigned to Nerviano Medical Sciences SRL · Expires 2019-01-04 · 7y expired

What this patent protects

本发明涉及N‑[5‑(3,5‑二氟‑苄基)‑1H‑吲唑‑3‑基]‑4‑(4‑甲基‑哌嗪‑1‑基)‑2‑(四氢吡喃‑4‑基氨基)‑苯甲酰胺的新晶型，其制备方法，其在治疗由失调的蛋白激酶活性引起的疾病中的应用以及含有它的药物组合物。

USPTO Abstract

本发明涉及N‑[5‑(3,5‑二氟‑苄基)‑1H‑吲唑‑3‑基]‑4‑(4‑甲基‑哌嗪‑1‑基)‑2‑(四氢吡喃‑4‑基氨基)‑苯甲酰胺的新晶型，其制备方法，其在治疗由失调的蛋白激酶活性引起的疾病中的应用以及含有它的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN109153669A
Jurisdiction
CN
Classification
—
Expires
2019-01-04
Drug substance claim
No
Drug product claim
No
Assignee
Nerviano Medical Sciences SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.